Validation of HB-EGF and amphiregulin as targets for human cancer therapy

Fusanori Yotsumoto, Hiroshi Yagi, Satoshi O. Suzuki, Eiji Oki, Hiroshi Tsujioka, Touru Hachisuga, Kenzo Sonoda, Tatsuhiko Kawarabayashi, Eisuke Mekada, Shingo Miyamoto

Research output: Contribution to journalArticlepeer-review

128 Citations (Scopus)


Aberrant expression levels of epidermal growth factor receptor (EGFR) and its cognate ligands have been recognized as one of the causes of cancer progression. To investigate the validity of EGFR ligands as targets for cancer therapy, we examined the expression of EGFR ligands and in vitro anti-tumor effects of small interference RNA (siRNA) for EGFR ligands in various cancer cells. HB-EGF expression was dominantly elevated in ovarian, gastric, and breast cancer, melanoma and glioblastoma cells, whereas amphiregulin was primarily expressed in pancreatic, colon, and prostate cancer, renal cell carcinoma and cholangiocarcinoma cells. Transfection of siRNAs for HB-EGF or amphiregulin into these cells significantly increased the numbers of apoptotic cells with attenuation of EGFR and ERK activation. In lung cancer cells, any EGFR ligand was not recognized as a validated target for cancer therapy. These results suggest that HB-EGF and amphiregulin are promising targets for cancer therapy.

Original languageEnglish
Pages (from-to)555-561
Number of pages7
JournalBiochemical and Biophysical Research Communications
Issue number3
Publication statusPublished - Jan 18 2008

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Validation of HB-EGF and amphiregulin as targets for human cancer therapy'. Together they form a unique fingerprint.

Cite this